Safirstein, Beth
for the TRAILBLAZER-ALZ 2 Investigators
3 papers on CoChat
Most cited papers
- Verified · note
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 2,932
- Verified
Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland, D., Brewer, J. B., Hagler, D. J., Fennema-Notestine, C., Dale, A. M., Initiative, T. A. D. N., Weiner, M., Thal, L., Petersen, R., Jack, C. R., et al. (2009) · Proceedings of the National Academy of Sciences
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 210
- Verified
A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
Black, R. S., Sperling, R. A., Safirstein, B., Motter, R. N., Pallay, A., Nichols, A., & Grundman, M. (2010) · Alzheimer Disease & Associated Disorders
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 170
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free